Table 1.

Individual characteristics and outcomes

Patient number	Malignancy	Therapy status (days since therapy)	Etiology of ARF	SAPS II	LIS	ECMO days	Bleeding	ICU and hospital outcome
1	CNS NHL	Chemotherapy (51)	Pneumonia	45	3.7	9	Minor	Died
2	Hodgkin lymphoma	Allo SCT (111)	Pneumonia	34	3.3	28b	Major	Died
3	ALL	Consolidation (13)	Abdominal sepsis	78	2.3	4c	-	Alive
4	ALLa	Induction on ECMO	TRALI	62	3.3	3	-	Alive
5	Burkitt lymphoma	Induction (16)	Pneumonia	63	3.8	8	-	Alive
6	ALL	Allo SCT (31)	Pneumonia	39	3.5	7	Major	Died
7	Hodgkin lymphoma	Allo SCT (33)	Pneumonia	65	3.3	18	-	Died
8	ALL	Allo SCT (203)	Pneumonia	68	3.3	10	-	Died
9	DLBCL	Induction on ECMO	Pneumonia	102	4.0	4	-	Died
10	Multiple myeloma	Auto SCT (789)	Pneumonia	43	3.7	9	Major	Alive
11	Anaplastic T-cell NHLa	Induction on ECMO	Pneumonia	46	3.0	25d	Major	Alive
12	DLBCLa	Induction on ECMO	NHL	36	3.3	3c	-	Alive
13	AML	Consolidation (34)	Pneumonia	48	3.3	34	Major	Died
14	DLBCLa	Induction on ECMO	NHL	56	2.3	4d	-	Alive

ALL, acute lymphoblastic leukemia; allo SCT, allogeneic stem cell transplantation; AML, acute myeloid leukemia; ARF, acute respiratory failure; auto SCT, autologous stem cell transplantation; CNS, central nervous system; DLBCL, diffuse large B-cell lymphoma; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; LIS, lung injury score at ECMO baseline [30]; NHL, non-Hodgkin lymphoma; SAPS II, simplified acute physiology score at ICU admission [27]; TRALI, transfusion-related acute lung injury. ^aDiagnosis of hematologic malignancy on ECMO; ^bTwo episodes of ECMO; ^cventoarterial ECMO; ^dthree episodes of ECMO.